Discovery of Selective Cannabinoid CB₂ Receptor Agonists by High-Throughput Screening.

ABSTRACT: The endocannabinoid system (ECS) plays a diverse role in human physiology ranging from the regulation of mood and appetite to immune modulation and the response to pain. Drug development that targets the cannabinoid receptors (CB₁ and CB₂) has been explored; however, success in the clinic has been limited by the psychoactive side effects associated with modulation of the neuronally expressed CB₁ that are enriched in the CNS. CB₂, however, are expressed in peripheral tissues, primarily in immune cells, and thus development of CB₂-selective drugs holds the potential to modulate pain among other indications without eliciting anxiety and other undesirable side effects associated with CB₁ activation. As part of a collaborative ef

SUBMITTER: Ogawa LM 

PROVIDER: S-EPMC6219460 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature